Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 12 systematic review(s)/meta-analysis(es). ^[1-12]
• Detection Rates for Biochemical Recurrence (BCR) by Prostate-Specific Antigen (PSA) Levels: Fluciclovine detection rates varied by PSA level, with 37% at PSA < 0.5 ng/mL, 44% at 0.5-0.99 ng/mL, and 61% at 1.0-1.99 ng/mL, while prostate-specific membrane antigen (PSMA) showed higher detection rates of 44%, 60%, and 80% for these PSA levels, respectively. In another study, PSMA demonstrated rates of 58%, 75%, 86%, and 94% for PSA levels < 0.5, 0.5-0.99, 1.0-1.99, and > 2.0 ng/mL, respectively.
• Primary Tumor Detection Accuracy: Fluciclovine and PSMA radiotracers had similar diagnostic accuracy for primary tumor detection in initial staging of high-risk prostate cancer, with sensitivity and specificity of 85% and 77% for fluciclovine and 84% and 83% for PSMA, respectively.
• Impact on Management and Outcomes: Fluciclovine Positron Emission Tomography (PET)/CT resulted in management changes in 59-63% of patients and was associated with improved failure-free survival when used in radiotherapy planning.
• Pooled Sensitivity and Specificity in Recurrence Detection: Fluciclovine showed a pooled sensitivity and specificity of 0.68 for detecting recurrence in relapsed prostate cancer patients.
• There is no safety information available in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.